an for to assume to I compelling large do for of saw host dedicated us first as to both my in NRx, build and private role both. CEO decided NRx Thank to call the industry and you, I morning, thank spent portion I'm When to today. quarterly Tom. Good a advancing to I benefit excited career and at science opportunity Pharmaceuticals. joining shareholders. my people everyone, leadership service, results you public value of
Officer. Officer; Financial and forward new Operations as Officer; We your we Chief calls us. Seth to the to and Jonathan this Head before appreciate realize Scientific Van endeavor this opportunities Commercial Chief Joining you Voorhees, and are me today Robert Chief on future Javitt, attendance in of our with Besthof, our work engaging and look
Before quarter balance the NRx. take wanted of plans few discussing year, at highlight me results opportunities and moments our second for to to this to what attracted a the I
portfolio. differentiation its point an with a scientific strong has unique and NRx a First, and NRx a property regulatory competitors. extraordinary between This of many is of organization, and robust and foundation the fact intellectual
the depressive NRX-XXX for also a all represent medications with commercial to am life-saving has that in our and that bringing team depression such franchise Second, and of and a delighted And of lead of seeks strong those significant asset, to PTSD value bipolar a other patients to opportunity. be medical mental address paradigm to effort I us. deliver leading potential significant psychiatry needs disorders. forms basis in record to with the for a unmet applications the renewed development of third, issues, NRX-XXX, treatment our change developing the major array track Together as health rapidly program market,
who suicidal Data both active studies of trials oral with To depression clinical only and in typically compared from reduction who with our NRX-XXX bipolar patients begin. the criteria knowledge, suicide, targets exclusion patients let's antidepressant a and shows ketamine. X were that one an in with in our standard So acutely depression is is and to and depression significant bipolar were clinical stabilized initially NRX-XXX. Phase of completed PTSD. previously which depression suicidality therapy
showing is are letter peer-reviewed ketamine, and these patients. achieved as FDA, correlated findings is The have read not new that therapy Columbia changes with NRX-XXX addictive. developmental FDA of other may potential you drug the Moreover, effects you NRX-XXX ketamine preclinical released for potential have biomarker bipolar offer option the granted University, non-addictive therapeutic achieves and reduce We NRX-XXX chemical oral are both by that commercial that shared only as changes key in advantages brain has to with statistically we the on the the been findings which NRX-XXX therapeutic psychiatry the in improvement also the a by nature depression. with unlike demonstrating component same from suicidality biomarker website. that its depression over and combined significant drugs in
stated commercialization. our NRX-XXX for milestones our advancing quarter, During we to second met
the project we catalysts would the Phase new sites, XX NRX-XXX about intended depression who of bipolar of sub-acute to and have trial of initiated our share enrollment and ideation for rest patients We activated patients has clinical sites. the me year. behavior, suicidal Let two-thirds represents which X in our and
that soon enrollment activated targeted depression being suicidality are study is ongoing. at do and hospitalization. require sites not bipolar Additional and This patients with XX-patient is
and Phase acute the to achieve larger population points. trial a being to suicidality patients to upgrade treated ambulatory as setting. study end aims substantial XXX,XXX release from in our outpatient the supply We X who trial enlargement manufactured FDA's patients bipolar received were XXX,XXX expect to potential on with indication patients in as this of the depression This of guidance X to primary secondary newly have treated soon drug our Phase we and sub-acute in and significantly
first forward has it patients of verge as $X the quarter also of in mentioned package. due the shown The to to drug of on increased suicide, thoughts be we trial desire opportunity. this of We study our suicide. and adding a the sub-acute needing potential project need the of Annual request a the these is were for the I and than XXXX clinicians rather to trial registration billion SSRI first the patients their of also who by data reduce to hospitalized look XXXX readout of for that at risk voiced even perhaps As introduced increase decrease of of NRX-XXX of the our Meeting antidepressants reflects the this view unlike many end or Shareholders, hospitalization. treat who to to
will potential During the restart and NRX-XXX NRX-XXX awarded FDA. be ideation in to the permit completion material, commercial level commercial this or part of second trial is first in XXXX. with filing by protocol drug advisers that under writing Phase agency study of approval. regulatory Conducting with successful agreement with for NDA the conducted suicidal trial FDA, new would trial the protocol our a of could our level special is we clinical to this and late as under designation NDA commercialization half data patients to basis as successful, the also us of XXXX, a and a or of X for said, Recall key year-end if agreement filing This advanced behavior with our breakthrough special I by the preparations material XXXX submitting application drug acute quarter, XXXX. to FDA rolling on lead with by as early mid-XXXX, by, the a
XXXX, first in manufacturer readiness stage. of to we the commercial North III preparedness Corporation half Carolina transferred During Alcami to and NRX-XXX for of order enable in Phase
we first overall initiate investment with IIb/III level of a need. broad Manufacturing our the help in our company. and position approval to franchise patent drug. psychiatry very of element believe a – of And our foundation to this readiness product, high differentiated patients psychiatry of achieving plan starting are manufactured is a recently This medicine. our unmet our crucial have study materials. for registrational we Phase to is new in a highly submission estate, is important with The We unique batch an to piece deliver area commercial medical
view unmet other PTSD. There unmet our Between have indications armed medical as in to our One-third and of XX exploring are as this X another suicide. considering need. with high PTSD We of are are country such medical and million XX severe also day every veterans very forces high PTSD. need lost experienced approximately individuals them that members suicidality. We
Our intellectual NRX-XXX. offers molecules a of NMDA antagonist, property including to a range a D-cycloserine, of component receptor of and variety combine options estate
Turning to ZYESAMI.
be by did stopped efficacy. area unpredictable COVID-XX As ACTIV-Xb [ph] read NIH an as done May, also desired out we was recently company the challenging with trial and not evidenced another in NIH announced another trial futility. continues the clinical for the to that for Taseko by
scores XX during options sub-study to that a our X-rays for treated sub-study of will from in Phase NIH COVID-XX ZYESAMI than X.XX. along with guided IIb subgroup respiratory received be X-ray independent with a less data was P statistically day a and chest future analysis with by approximately of from a patients we significant ZYESAMI in in had of worsening includes study. data, XX survived assessment This an failure that to that improvement rail compared Our using patients placebo of X independent chest assessment patients showed
an completed in Earlier early data NIH quarter, quarter the X/commercial this analysis independent fourth late time. at phase manufacture we'll of receive and – to expect we year, third We ZYESAMI. conduct ready late or the this
We ZYESAMI to not Seth? trials I funding brief it time. for are With additional over that, financial Seth results. this turn of at overview will our at a
